Cardiovascular

Recurrent pericarditis: colchicine and adjunctive therapy

Clinical Overview and When to Suspect Recurrent Pericarditis

— Incessant pericarditis: symptoms persist >4–6 weeks without remission (distinct concept, often managed similarly).

— Chronic pericarditis: lasting >3 months continuously.

— Autoimmune/autoinflammatory (lupus, RA, IgG4, FMF, TRAPS)

— Post-cardiac injury syndromes (post-MI Dressler, post-pericardiotomy, post-ablation, post-PCI)

— Uremia, hypothyroidism, malignancy, TB (think in immigrants/HIV)

— Drug-induced (hydralazine, procainamide, isoniazid, immune checkpoint inhibitors)

— Young to middle-aged adult returns weeks–months after a prior "viral pericarditis" with recurrent pleuritic chest pain relieved by sitting forward.

— Patient recently tapered or discontinued NSAIDs/colchicine and now has new symptoms.

— Post-CABG or post–AF ablation patient at 2–8 weeks with low-grade fever, malaise, and chest pain.

Board pearl: A patient who "did fine on ibuprofen + colchicine for 3 months, then stopped both abruptly" and returns with the same pain is the prototypical recurrent pericarditis stem — answer is to resume the prior regimen and taper more slowly, not to escalate to steroids first. Always check CRP at presentation; it guides duration of therapy and tapering cadence.

Definition: Recurrent pericarditis = new episode of acute pericarditis after a symptom-free interval of ≥4–6 weeks following a prior documented episode.

Epidemiology: 15–30% of first idiopathic acute pericarditis cases recur if not treated with colchicine; recurrence drops to ~10–15% when colchicine is added to NSAIDs upfront.

Etiology (≥80% idiopathic/viral in developed countries):

When to suspect on Step 3:

Diagnostic threshold: Need ≥2 of 4 criteria (typical chest pain, friction rub, new widespread ST elevation or PR depression, new/worsening effusion); supportive features include ↑CRP and pericardial inflammation on CMR.

Presentation Patterns and Key History

— Positional: worse supine, relieved leaning forward (classic).

— Radiates to trapezius ridge (phrenic nerve innervation of pericardium) — highly specific.

— Worse with inspiration, cough, swallowing.

— Low-grade fever (>38°C suggests bacterial/purulent — escalate)

— Dyspnea (effusion or pleuritic splinting)

— Fatigue, malaise, myalgias in viral/autoimmune recurrences

— Prior episode details: date, treatment received, response, taper schedule, CRP normalization

— Adherence and taper: Did the patient stop colchicine early? Taper NSAIDs over <2 weeks?

— Triggers: recent viral URI, cardiac surgery (4–6 weeks prior), MI, catheter ablation, chest radiation

— Autoimmune review of systems: rash, arthralgias, oral ulcers, Raynaud, sicca → screen for SLE

— Travel/exposure: TB risk (incarceration, homelessness, immigration from high-prevalence regions, HIV)

— Medications: new hydralazine, procainamide, ICI therapy (pembrolizumab, nivolumab — increasingly tested)

— Family history: familial Mediterranean fever (FMF), TRAPS — consider in Mediterranean/Middle Eastern ancestry with recurrent fevers + serositis

— Fever >38°C, subacute onset, large effusion (>20 mm), tamponade physiology

— Immunosuppression, oral anticoagulation, trauma

— Failure to respond to NSAIDs after 7 days

— Elevated troponin (myopericarditis)

Step 3 management: Outpatient management is appropriate for uncomplicated, low-risk recurrent pericarditis. The decision tree: assess risk features first → if none and CRP elevated with typical pain, treat as outpatient with NSAID + colchicine and follow CRP weekly. If any high-risk feature → admit. Document a clear taper plan at the index visit; abrupt discontinuation is the single most common cause of recurrence appearing on board exams.

Cardinal symptom: Sharp, pleuritic, retrosternal chest pain.

Associated features:

History elements to mine in the Step 3 stem:

Red flags warranting hospitalization (high-risk features):

Physical Exam Findings and Hemodynamic Assessment

— Scratchy, leathery, triphasic (atrial systole, ventricular systole, early diastole) in ~50%; often monophasic or evanescent.

— Best heard at left lower sternal border, patient leaning forward, breath held in end-expiration.

— Highly specific but insensitive (~30–35% sensitivity in recurrent disease — often absent).

— Tachycardia common; fever >38°C is a red flag.

— Hypotension, narrow pulse pressure → think tamponade.

— Beck triad: hypotension, muffled heart sounds, JVD (full classic triad <40%).

— Pulsus paradoxus >10 mmHg: drop in systolic BP with inspiration; measure with manual cuff.

— Kussmaul sign (rise in JVP with inspiration) → more typical of constriction than tamponade.

— Y descent: blunted in tamponade, prominent in constriction.

— Pericardial knock (early diastolic, higher pitched than S3)

— Hepatomegaly, ascites, peripheral edema out of proportion to pulmonary congestion

— Square-root sign and dip-and-plateau on cath

— Ewart sign: dullness/bronchial breathing at left scapular tip from compression of left lower lobe by large effusion.

— Malar rash, oral ulcers, synovitis → SLE

— Uremic frost, AV fistula → uremic pericarditis

— Lymphadenopathy, weight loss → malignancy or TB

Key distinction: Tamponade vs constriction — both cause elevated JVP and Kussmaul-like findings, but tamponade has pulsus paradoxus and blunted Y descent, while constriction has prominent Y descent and a pericardial knock. Mixed effusive-constrictive physiology can occur after partial pericardiocentesis when underlying constriction is unmasked — a favored Step 3 trap. Always reassess hemodynamics post-drainage and obtain echo within 24 hours.

Pericardial friction rub:

Vital signs:

Tamponade physiology — must recognize:

Constrictive features (in chronic/recurrent disease):

Effusion exam:

General exam clues to etiology:

Diagnostic Workup — Initial Labs, ECG, and Imaging

— Stage 1: diffuse concave-up ST elevation + PR depression (PR elevation in aVR is reciprocal — highly specific).

— Stage 2: normalization (days). Stage 3: diffuse T-wave inversions. Stage 4: resolution.

— In recurrent pericarditis, ECG changes are often subtle or absent — fibrotic/scarred pericardium responds less; do not rely on classic ECG.

— No reciprocal ST depression (vs STEMI) except in aVR and V1.

— CBC: leukocytosis common

— CRP and ESR: elevated in 75–80%; CRP is the key biomarker for monitoring and guiding taper — recheck weekly until normal

— Troponin: if elevated → myopericarditis (changes management: restrict exercise, consider hospitalization, avoid high-dose NSAIDs in some cases)

— BUN/Cr: rule out uremic pericarditis

— TSH: hypothyroidism can cause effusion

— HIV, ANA, RF, anti-CCP: if recurrent/atypical features; targeted autoimmune workup

— Quantiferon-Gold or PPD: if TB risk

— Blood cultures if febrile or purulent suspected

— Cardiomegaly ("water-bottle heart") only if effusion >250 mL

— Look for pulmonary infiltrates, mediastinal widening

— Assess effusion size (small <10 mm, moderate 10–20 mm, large >20 mm in diastole)

— Tamponade signs: RA systolic collapse (sensitive), RV diastolic collapse (specific), respiratory variation in mitral inflow >25% and tricuspid inflow >40%, IVC plethora

Board pearl: CRP is the workhorse biomarker in recurrent pericarditis management. Continue anti-inflammatory therapy until CRP normalizes, then begin taper. Tapering based on symptoms alone (with persistently elevated CRP) is the #1 reason for recurrence on boards. Order CRP at diagnosis, at 1 week, then biweekly through taper.

ECG (obtain in every suspected case):

Labs:

Chest X-ray:

Transthoracic echocardiogram (every case):

Advanced and Confirmatory Studies

— Gold standard for confirming active pericardial inflammation in recurrent/atypical cases

— Pericardial LGE = active inflammation → predicts response to anti-inflammatory therapy and risk of recurrence

— Pericardial thickening >4 mm, edema on T2 imaging

— Useful when diagnosis is uncertain (normal CRP, atypical pain) or for guiding duration of therapy

— Distinguishes effusive-constrictive physiology and detects myocardial involvement (myopericarditis)

— Calcified pericardium (constrictive pericarditis — TB, post-radiation)

— Useful when echo windows are poor or for surgical planning

— Suspected purulent, tuberculous, or malignant pericarditis

— Large effusion (>20 mm) without clear etiology after 1 week of empiric therapy

— Therapeutic: tamponade (always)

— Send fluid for: cell count, Gram stain, culture, AFB smear/culture, cytology, adenosine deaminase (ADA — elevated in TB), LDH, glucose, protein

— Reserved for refractory cases with persistent effusion and unclear diagnosis after pericardiocentesis

— Performed at time of pericardial window

— If constrictive vs restrictive cardiomyopathy is in question

— Equalization of diastolic pressures, dip-and-plateau, discordance of LV/RV systolic pressures with respiration (constriction)

— Consider in pediatric or familial recurrent pericarditis: MEFV (FMF), TNFRSF1A (TRAPS), NLRP3 — these autoinflammatory syndromes respond dramatically to IL-1 blockade

Step 3 management: Order CMR with LGE in any patient with a second recurrence, atypical features, or normal CRP but persistent symptoms — it confirms ongoing inflammation and justifies escalation to steroids, IL-1 blockers, or extended colchicine. CMR also identifies who can safely taper vs who needs prolonged therapy.

Cardiac MRI (CMR) with late gadolinium enhancement (LGE):

CT chest:

Pericardiocentesis — diagnostic indications:

Pericardial biopsy:

Right heart catheterization:

Genetic testing:

Risk Stratification and Management Logic

— High-risk major features: fever >38°C, subacute onset, large effusion (>20 mm), tamponade, failure to respond to NSAID + colchicine after 7 days

— Minor features: myopericarditis (↑troponin), immunosuppression, trauma, oral anticoagulation

— Any major or minor feature → hospitalize and search for specific etiology

— No features → outpatient management with empiric NSAID + colchicine

1. Achieve symptom resolution and CRP normalization

2. Prevent next recurrence with adequate duration + slow taper

3. Avoid corticosteroid dependence

4. Identify treatable underlying cause

— Tier 1: NSAID (ibuprofen, ASA, or indomethacin) + colchicine ≥6 months

— Tier 2 (NSAID intolerance or contraindication): low-dose prednisone (0.2–0.5 mg/kg/day) + colchicine

— Tier 3 (multiple recurrences, steroid-dependent): IL-1 blockade — anakinra or rilonacept (FDA-approved 2021 for recurrent pericarditis)

— Tier 4 (refractory): azathioprine, IVIG, or pericardiectomy

— Avoid strenuous exercise until symptom-free, CRP normal, ECG and echo normalized

— Athletes: ≥3 months of restriction; longer if myopericarditis

— Purulent → drainage + IV antibiotics

— TB → RIPE therapy

— Uremic → intensify dialysis

— Autoimmune → treat underlying disease

Board pearl: Avoid corticosteroids as first-line in recurrent pericarditis whenever possible — they paradoxically increase recurrence rates by impairing viral clearance and altering immune resolution. Reserve for NSAID contraindication, pregnancy (after 20 weeks), or specific autoimmune etiologies. If used, low dose (0.2–0.5 mg/kg/day) with very slow taper over months, always with concomitant colchicine.

Risk stratification at presentation (ESC framework):

Treatment goals in recurrence:

Tiered management ladder (memorize this for Step 3):

Activity restriction:

Etiology-specific treatment supersedes empiric anti-inflammatories:

Pharmacotherapy — First-Line Regimen

NSAID options (choose one, attack dose × 1–2 weeks then taper over 2–4 weeks):

— Ibuprofen 600–800 mg PO TID (most common)

— Aspirin 750–1000 mg PO TID (preferred post-MI/Dressler and in patients on antiplatelet therapy)

— Indomethacin 25–50 mg PO TID (more GI toxicity, avoid in elderly)

— Add PPI for GI protection in all patients

— Continue until symptoms resolved AND CRP normalized, then taper by ~25% every 1–2 weeks

Colchicine (the pillar of recurrence prevention):

— Dose: 0.5 mg PO BID if ≥70 kg; 0.5 mg PO daily if <70 kg or elderly

— Duration in recurrence: ≥6 months (vs 3 months for first episode); often 12+ months

— No loading dose (unlike gout)

— Mechanism: inhibits microtubule polymerization → blocks NLRP3 inflammasome and neutrophil activation

— Adverse effects: diarrhea (10–15%, dose-limiting), nausea, transaminitis, myopathy, cytopenias

— Drug interactions (critical): CYP3A4 and P-glycoprotein inhibitors raise levels dangerously — clarithromycin, erythromycin, diltiazem, verapamil, cyclosporine, statins (especially simvastatin — risk of rhabdomyolysis), grapefruit juice, strong avoidance with clarithromycin in renal impairment

— Renal dosing: reduce or avoid if CrCl <30; contraindicated in dialysis

— Hepatic dosing: avoid in severe hepatic impairment

Monitoring during therapy:

— CBC, CMP at baseline, 1 month, then every 3 months

— CRP weekly until normal, then at each taper step

— Symptom diary

Step 3 management: When a recurrence occurs during a colchicine taper or shortly after stopping, resume the full dose of colchicine and NSAID, continue until CRP normalizes, then taper over a longer period (often 12 months total). Do not jump to steroids unless NSAID-contraindicated. Counsel explicitly that stopping colchicine early is the most common preventable cause of recurrence.

NSAID + colchicine is the cornerstone for the acute episode of a recurrence.

Adjunctive and Advanced Therapy — IL-1 Blockade and Beyond

— Indications: NSAID contraindication (CKD, severe GI disease, pregnancy >20 weeks, anticoagulation), specific autoimmune cause, failure of NSAID + colchicine

— Prednisone 0.2–0.5 mg/kg/day (low dose preferred — high dose increases recurrence)

— Always combine with colchicine

— Taper very slowly over months; reduce by 5–10 mg every 2–4 weeks until 25 mg, then 2.5 mg every 2–4 weeks, then 1 mg

— Pause taper at any recurrence or CRP rise

— Add calcium, vitamin D, bisphosphonate per steroid bone-health guidelines

— Rilonacept — IL-1α and IL-1β trap, FDA-approved 2021 for recurrent pericarditis

— Dose: 320 mg SC loading, then 160 mg SC weekly

— RHAPSODY trial: 96% reduction in recurrence risk vs placebo

— Anakinra — recombinant IL-1 receptor antagonist

— 100 mg SC daily; used off-label, supported by AIRTRIP trial

— Daily injection site reactions common

— Indications: ≥2 recurrences despite NSAID + colchicine + steroids, steroid dependence, contraindication to standard therapy

— Screen before starting: TB (Quantiferon), hepatitis B, vaccinations up to date (no live vaccines on therapy)

— Adverse effects: injection site reactions, infections, neutropenia, transaminitis

— Azathioprine 1.5–2.5 mg/kg/day — steroid-sparing in autoimmune cases (check TPMT first)

— IVIG — particularly in autoimmune/viral overlap

— Methotrexate, hydroxychloroquine — if underlying connective tissue disease

— Last resort for refractory pain or constriction

— High-volume center; mortality 5–10%; symptom relief variable

Board pearl: A patient on chronic prednisone with third recurrence on attempted taper — the right answer on Step 3 is now add rilonacept (or anakinra) and begin steroid taper, not increase the steroid dose. IL-1 blockade is the modern standard for steroid-dependent recurrent pericarditis.

Corticosteroids (second-line; use sparingly):

IL-1 blockade (game-changer for refractory/steroid-dependent disease):

Other options for refractory disease:

Pericardiectomy:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher NSAID risks: GI bleeding, AKI, heart failure exacerbation, hypertension

— Prefer aspirin over ibuprofen/indomethacin when feasible (better CV safety profile)

— Always co-prescribe PPI

— Colchicine: start at 0.5 mg daily (not BID); monitor for diarrhea and myopathy

— Check eGFR before every dose adjustment

— Polypharmacy review: statin interactions (rhabdomyolysis risk), CCBs (diltiazem/verapamil raise colchicine levels)

— NSAIDs: avoid if eGFR <30; use with caution at 30–60 with close monitoring of Cr and K

— Colchicine dosing by CrCl:

— CrCl >50: standard dose

— CrCl 30–50: reduce to 0.5 mg daily; monitor closely

— CrCl <30: 0.5 mg every 2–3 days OR avoid

— Dialysis: contraindicated (not dialyzable, accumulates → fatal myelosuppression and neuromyopathy)

— Steroids become first-line option in advanced CKD

— Uremic pericarditis specifically: intensify dialysis (5–7×/week) — anti-inflammatories play secondary role

— NSAIDs: avoid in decompensated cirrhosis (variceal bleeding, hepatorenal syndrome)

— Colchicine: reduce dose in moderate impairment; avoid in severe (Child-Pugh C)

— Steroids: caution; can precipitate hepatic encephalopathy via fluid retention

— Consider IL-1 blockade earlier in this group

— Higher hemorrhagic effusion risk

— Prefer steroids over NSAIDs to minimize bleeding

— Colchicine remains safe and indicated

— Monitor effusion size with serial echo

Key distinction: Uremic pericarditis (BUN typically >60) responds to dialysis intensification, not primarily to NSAIDs/colchicine. Dialysis-associated pericarditis in an already-dialyzed patient is treated with intensified, heparin-free dialysis and consideration of pericardiocentesis if effusion enlarges — colchicine is contraindicated in dialysis patients regardless.

Elderly (≥65 years):

Renal impairment:

Hepatic impairment:

Anticoagulated patients:

Special Populations — Pregnancy and Pediatrics

— Recurrent pericarditis often flares peripartum due to immunologic shifts

— First and second trimester (up to 20 weeks): aspirin or ibuprofen acceptable; avoid late in second trimester

— After 20 weeks: NSAIDs contraindicated — risk of premature closure of ductus arteriosus, oligohydramnios, fetal renal injury

— Colchicine: historically avoided but now considered safe in pregnancy and lactation based on FMF cohort data; continue if benefit outweighs risk after shared decision-making

— Prednisone (low dose) is the preferred agent after 20 weeks gestation — minimally crosses placenta (metabolized by placental 11-β-HSD)

— Avoid IL-1 blockers, methotrexate, azathioprine in pregnancy planning unless absolutely necessary; methotrexate is teratogenic and contraindicated

— Pre-conception counseling: ensure disease quiescent ≥6 months; transition off teratogenic agents

— NSAIDs (ibuprofen preferred), low-dose prednisone, colchicine all considered compatible

— Anakinra likely compatible (minimal oral absorption); rilonacept data limited

— Often autoinflammatory: consider FMF (MEFV), TRAPS, CAPS — refer to rheumatology

— Aspirin avoided due to Reye syndrome — use ibuprofen as first-line NSAID

— Colchicine weight-based: 0.5–1.5 mg/day divided

— IL-1 blockade highly effective, often first-line for autoinflammatory pediatric cases

— Avoid prolonged steroids → growth suppression

— Occurs 1–6 weeks post-op in 10–40% of cardiac surgery patients

— Colchicine prophylaxis (started post-op) reduces PPS by ~50% — supported by COPPS and COPPS-2 trials

— Treat established PPS as recurrent pericarditis: NSAID + colchicine

Step 3 management: A 28-year-old at 24 weeks gestation with second recurrence — the correct order is stop NSAID, start low-dose prednisone, continue colchicine, and arrange MFM co-management. Document shared decision-making about colchicine continuation; this is a common board scenario.

Pregnancy:

Lactation:

Pediatric recurrent pericarditis:

Post-cardiac surgery (post-pericardiotomy syndrome — PPS):

Complications and Adverse Outcomes

— Small effusions resolve in 60–70%; large effusions in ~20% progress to tamponade

— Recurrent effusions may organize → fibrosis → constriction

— Acute decompensation; obstructive shock

— Pulsus paradoxus >10 mmHg, JVD, hypotension, muffled sounds

— Emergency pericardiocentesis (echo-guided preferred over blind subxiphoid)

— Avoid positive-pressure ventilation if possible until drained (reduces preload)

— <1% in idiopathic; up to 30% in TB; intermediate in post-surgical

— Presents with right-sided heart failure: edema, ascites, hepatic congestion

— Transient constriction (resolves with anti-inflammatory therapy in 2–3 months) is distinct from chronic constriction — trial of medical therapy before pericardiectomy if recent inflammation

— Chronic constriction → pericardiectomy is definitive

— Elevated troponin with preserved or mildly reduced LV function

— Activity restriction ≥3–6 months

— Avoid high-intensity exercise; serial CMR

— Generally good prognosis if LV function preserved

— NSAID: GI bleeding, AKI, HTN, edema

— Colchicine: diarrhea, myopathy, cytopenias, fatal toxicity in overdose or with CYP3A4 inhibitors

— Corticosteroids: weight gain, hyperglycemia, osteoporosis, infections, adrenal suppression, rebound pericarditis on rapid taper

— IL-1 blockers: infection risk, injection reactions, neutropenia

— Recurrent chest pain causes significant anxiety, depression, ED visits

— Loss of work productivity; counseling and patient education are integral

— Idiopathic recurrent pericarditis: mortality essentially 0%; reassure patients

— Purulent, neoplastic, TB pericarditis carry significant mortality

Board pearl: A patient with recurrent pericarditis on chronic steroids develops new exertional dyspnea and ascites — think constriction (effusive-constrictive or chronic). Order CMR and right heart cath; medical therapy first if active inflammation present (transient constriction), pericardiectomy if chronic and fibrotic. Don't miss this transition.

Pericardial effusion progression:

Cardiac tamponade:

Constrictive pericarditis:

Myopericarditis:

Drug-related complications:

Psychosocial complications:

Mortality:

When to Escalate — Inpatient Triage and Consults

— Tamponade physiology → ICU + emergent pericardiocentesis

— Large effusion (>20 mm) even without tamponade — observation and possible drainage

— Suspected purulent pericarditis (high fever, septic appearance) → ICU, IV antibiotics, drainage

— Elevated troponin (myopericarditis) → telemetry/step-down; arrhythmia monitoring

— Hemodynamic instability of any cause

— Failure of outpatient NSAID + colchicine after 7 days

— Immunosuppression, oral anticoagulation with new effusion, recent trauma

— Cardiology: every recurrence; mandatory if effusion, myopericarditis, or refractory

— Rheumatology: ≥2 recurrences, autoimmune features, or considering IL-1 blockade

— Infectious disease: suspected TB, purulent, HIV-related, or immunosuppressed

— Cardiothoracic surgery: tamponade requiring window, suspected constriction, refractory effusion

— MFM: any pregnant patient with recurrent pericarditis

1. IV access, continuous telemetry, pulse oximetry

2. ECG, CBC, BMP, troponin, CRP, ESR, BNP, blood cultures, TSH

3. Stat bedside echocardiogram — assess effusion and tamponade

4. CXR

5. If tamponade → pericardiocentesis (echo- or fluoroscopy-guided) — send fluid for cell count, Gram stain, culture, AFB, cytology, ADA

6. Begin ibuprofen 800 mg TID + colchicine 0.5 mg BID + PPI

7. If purulent suspected: empiric vancomycin + ceftriaxone pending cultures

8. Cardiology consult

9. Serial CRP, daily echo if moderate effusion, telemetry

— Hemodynamically stable, effusion not enlarging, pain controlled on PO regimen, CRP trending down, clear taper plan, follow-up within 1–2 weeks

CCS pearl: On the CCS interface, always advance the clock in short increments (2–4 hours) after pericardiocentesis to monitor for re-accumulation or hemodynamic deterioration. Repeat echo within 12–24 hours. Do not discharge from the ICU until effusion stability is documented.

Admit immediately (ED disposition criteria):

Consults to obtain:

CCS ordering sequence for high-risk presentation:

Discharge criteria from inpatient stay:

Key Differentials — Same-Category (Pericardial/Cardiac) Causes

— Same clinical syndrome but no prior documented episode

— Recurrence definition requires a symptom-free interval; if continuous → incessant pericarditis

— Treatment identical (NSAID + colchicine) but colchicine duration shorter (3 months vs 6+ months)

— Same syndrome plus elevated troponin and possibly reduced EF or wall motion abnormalities

— Avoid intense NSAID dosing in some protocols; emphasize activity restriction

— CMR distinguishes from pure myocarditis (LGE pattern: epicardial/mid-wall in myocarditis vs pericardial enhancement)

— Right-sided HF predominance, no pleuritic pain

— Pericardial knock, prominent Y descent, Kussmaul sign

— Echo: septal bounce, respiratory variation; CMR: thickened pericardium

— Hypothyroidism, malignancy, uremia, post-radiation — may be painless

— No CRP elevation, no rub, ECG often normal apart from low voltage

— Dressler syndrome (post-MI, weeks later, immune-mediated)

— Post-pericardiotomy syndrome (post-cardiac surgery, weeks later)

— Post-ablation pericarditis (after AF ablation — increasing on boards)

— All treated similarly; colchicine prophylaxis effective in surgical population

— ST elevation in regional distribution, reciprocal depressions, troponin elevation

— Pain not positional, not relieved by leaning forward

— Echo shows regional wall motion abnormality, not effusion

— Coronary angiography if doubt persists

Key distinction: STEMI vs acute pericarditis ECG — STEMI has localized ST elevation in a coronary distribution with reciprocal depression; pericarditis has diffuse concave-up ST elevation with PR depression and no reciprocal changes (except aVR/V1). When in doubt with a recurrent pericarditis patient who has new pain, always obtain troponin and serial ECGs; the prior diagnosis does not exempt them from new ACS.

Acute pericarditis (first episode):

Myopericarditis:

Constrictive pericarditis:

Pericardial effusion without pericarditis:

Post-cardiac injury syndromes:

Acute coronary syndrome (the must-not-miss):

Key Differentials — Other-Category Causes

— Pleuritic chest pain + dyspnea; may have hypotension

— Tachycardia, S1Q3T3, T-wave inversions V1–V4 (RV strain)

— D-dimer, CT-PA distinguish; troponin can be elevated in massive PE

— No pericardial effusion typically; no diffuse ST elevation

— Pleuritic pain, fever, cough, focal lung findings

— Infiltrate on CXR; CRP elevated but ECG normal

— Pleural rub (not pericardial) — does not vary with cardiac cycle

— Tearing pain radiating to back; pulse asymmetry; widened mediastinum

— Can cause pericardial effusion/tamponade (type A with proximal extension)

— CT angiography is diagnostic; do not delay

— Burning, postprandial; relieved by antacids

— Not positional in classic pericardial pattern; no rub, no ECG changes

— Reproducible with palpation

— No fever, no CRP elevation typically

— Dermatomal burning pain preceding rash by 3–5 days

— Consider if elderly or immunocompromised

— SLE: young woman with serositis, malar rash, cytopenias → check ANA, dsDNA, complement

— RA: known disease + new pericardial effusion

— Mixed connective tissue, scleroderma, vasculitides

— Treatment includes disease-specific immunosuppression

— Lung, breast, lymphoma, melanoma metastases to pericardium

— Bloody effusion; cytology positive

— Recurrent effusions despite drainage → pericardial window

Board pearl: A young woman with third pericarditis recurrence, fatigue, joint pains, and a malar rash — the answer is send ANA, anti-dsDNA, C3/C4, urinalysis and refer to rheumatology. Recurrent pericarditis can be the presenting feature of SLE; treating the underlying disease (hydroxychloroquine, immunosuppression) is more effective than escalating anti-pericarditis therapy alone.

Pulmonary embolism:

Pneumonia / pleurisy:

Aortic dissection:

GERD / esophageal spasm:

Musculoskeletal (costochondritis, Tietze):

Herpes zoster (preeruptive):

Connective tissue disease flare presenting as pericarditis:

Malignancy:

Secondary Prevention and Long-Term Plan

— Colchicine: ≥6 months for first recurrence; 12+ months for subsequent recurrences

— NSAID: until symptoms resolve and CRP normalizes, then taper over 2–4 weeks

— Steroids (if used): taper over months, never weeks

— IL-1 blockers (rilonacept/anakinra): typically continued ≥12 months once stable, then attempt taper

— Taper one drug at a time, never simultaneously

— Wait until CRP has been normal for ≥1 week before initiating taper

— Reduce by ~25% increments every 2 weeks

— Pause or reverse taper at any symptom return or CRP rise

— Document the taper schedule explicitly in discharge instructions

— Exercise restriction: no competitive or strenuous activity until symptom-free, normal ECG, normal echo, normal CRP — usually ≥3 months in recurrence; longer in myopericarditis

— Gradual return guided by symptoms and biomarkers

— Avoid known triggers (some patients identify stress, sleep deprivation, viral illness)

— Annual influenza vaccine (reduces viral pericarditis triggers)

— COVID-19 vaccination — generally safe; weigh risk if temporal association with prior episode

— Pneumococcal per age guidelines

— No live vaccines while on IL-1 blockade, high-dose steroids, or other immunosuppressants

— Hepatitis B screening/vaccination before biologic initiation

— Calcium 1000–1200 mg/day, vitamin D 800–2000 IU/day

— DEXA scan baseline; bisphosphonate if T-score <−1.5 or chronic prednisone >7.5 mg/day for >3 months

— Symptom diary, home thermometer for fever

— Clear instructions on when to seek care (chest pain, dyspnea, syncope)

Step 3 management: Discharge planning is high yield — every Step 3 recurrent pericarditis case should end with: written taper schedule, follow-up in 1–2 weeks with repeat CRP, prescriptions for ≥6 months of colchicine, NSAID with PPI, and clear return precautions. The exam loves checking that you scheduled follow-up before discharge.

Duration of therapy in recurrence (memorize):

Tapering principles (the heart of preventing recurrence):

Lifestyle and activity:

Vaccinations:

Bone health on chronic steroids:

Patient self-management:

Follow-Up, Monitoring Parameters, and Counseling

— Week 1–2: clinic visit; symptoms, exam, CRP, CBC, CMP

— Week 4: repeat CRP, decide on initiating taper if normalized

— Months 2–3: monthly visits during taper; echo at month 1 and 3 to track effusion

— Month 6 and beyond: every 3 months until off therapy ≥6 months without recurrence

— Repeat echo at any symptom recurrence

— CRP: primary biomarker; trend until normal, then at each taper step

— CBC: colchicine and biologics can cause cytopenias

— LFTs and renal function: baseline, monthly initially, then quarterly

— CK if myopathy symptoms (colchicine + statin risk)

— TB screening annually if on biologics

— At diagnosis, 1 week (if effusion), 1 month, 3 months

— Watch for: effusion size, signs of constriction (septal bounce, respiratory variation), LV function

— Adherence is everything: explain that colchicine prevents the next episode and must be taken even when feeling well

— Diarrhea is common but manageable with dose reduction; do not self-discontinue

— Avoid grapefruit juice, clarithromycin/erythromycin, certain statins without checking

— Bring medication list to every visit

— When traveling, ensure adequate supply

— Pregnancy planning: discuss before conception; transition off teratogenic agents

— Structured program valuable in deconditioned patients post-myopericarditis or post-pericardiectomy

— Begin only after clearance (symptom-free, biomarkers normal)

— Screen for anxiety/depression; recurrent disease is emotionally taxing

— Refer for CBT or pharmacotherapy as needed

CCS pearl: On a CCS case, after stabilizing the patient and starting therapy, schedule the clinic follow-up appointment and order outpatient CRP before ending the case. Common missed actions that cost points: not ordering follow-up labs, not scheduling clinic visits, not counseling on medication adherence and red-flag symptoms.

Follow-up cadence:

Monitoring parameters during therapy:

Echocardiographic surveillance:

Patient counseling (high yield for Step 3):

Cardiac rehabilitation:

Mental health:

Ethical, Legal, and Patient Safety Considerations

— High cost ($200,000+/year for rilonacept) — discuss financial toxicity, prior authorization, manufacturer assistance programs

— Discuss infection risk, vaccination requirements, TB and hep B screening

— Document shared decision-making, especially before initiation in patients of childbearing age

— Adrenal suppression: any patient on prednisone >5 mg/day for >3 weeks requires stress-dose steroid coverage for surgery, sepsis, trauma — communicate clearly in handoffs and medical records

— Counsel against abrupt discontinuation; provide a steroid emergency card

— Document bone health protocol initiation

— Drug-interaction-mediated toxicity is a leading cause of fatal medication error in this population

— Hard stop on clarithromycin co-prescription in CKD patients on colchicine — pharmacy alerts are essential

— Reconcile medications at every visit; explicitly check for new statins, CCBs, antifungals

— Counsel about grapefruit juice (often missed)

— At hospital discharge, the single highest-risk moment for recurrence is medication misunderstanding — provide written taper schedule in plain language, with dates

— Send notification to PCP within 24–48 hours

— Use teach-back to confirm patient understanding of taper

— Document objective criteria for clearance (symptom-free, normal CRP/ECG/echo)

— Provide written clearance; understand school/professional team requirements

— Premature clearance carries legal and clinical liability

— Shared decision-making for colchicine continuation; document discussion of evidence and patient preferences

— Avoid paternalistic decision-making; engage MFM

— TB pericarditis: mandatory reporting to public health + contact tracing

— HIV: reporting per state law

— Suspected drug-induced (e.g., hydralazine, ICI): consider FDA MedWatch reporting

Board pearl: A patient on chronic colchicine is prescribed clarithromycin by an urgent care for sinusitis and develops pancytopenia and rhabdomyolysis a week later — this is the classic colchicine drug-interaction patient-safety vignette. The answer focuses on systems-based error prevention: pharmacy alerts, medication reconciliation, patient education, and clear communication across care settings.

Informed consent for biologic therapy (rilonacept/anakinra):

Steroid-related safety:

Colchicine safety hazards (high-frequency Step 3 patient safety items):

Transitions of care:

Athletes and disability/return-to-play:

Pregnancy decision-making:

Reportable conditions:

High-Yield Associations and Rapid-Fire Facts

Key distinction: First episode vs recurrence drug duration — first episode of acute pericarditis = colchicine for 3 months; recurrence = colchicine for ≥6 months, often 12+ months. This single fact distinguishes a Step 3 clinician from a Step 2 one and is frequently tested.

PR depression in pericarditis ECG → highly specific; PR elevation in aVR is the reciprocal change

Colchicine reduces recurrence by ~50% when added to NSAID (CORP, ICAP, CORP-2 trials)

CRP normalization guides duration of therapy and taper timing — most important single biomarker

Steroids increase recurrence risk when used as first-line; reserve for specific indications

Rilonacept = FDA-approved IL-1 trap (2021) for recurrent pericarditis; RHAPSODY trial

Anakinra = IL-1 receptor antagonist, daily SC; effective for steroid-dependent disease

Dressler syndrome = post-MI pericarditis, 2–8 weeks later, immune-mediated; rare in PCI era

Post-pericardiotomy syndrome = post-cardiac-surgery pericarditis, prevented by colchicine 1 mg/day started post-op (COPPS, COPPS-2)

Pericardial friction rub: triphasic, best at LLSB with patient leaning forward

Pulsus paradoxus >10 mmHg → tamponade

Kussmaul sign → constriction (not tamponade)

Prominent Y descent → constriction; blunted Y descent → tamponade

Ewart sign → large pericardial effusion compressing left lower lobe

Beck triad = hypotension + JVD + muffled heart sounds (tamponade)

Pericardial calcification on CXR/CT → suggests TB pericarditis or chronic constriction

Adenosine deaminase (ADA) >40 U/L in pericardial fluid → TB pericarditis

CMR pericardial LGE = active inflammation; predicts response to anti-inflammatory therapy

FMF (MEFV mutation) + recurrent pericarditis → colchicine highly effective; IL-1 blockade if refractory

Colchicine + clarithromycin in CKD = potentially fatal interaction

Colchicine contraindicated in dialysis

Aspirin preferred in post-MI Dressler and in patients already on antiplatelet therapy

No NSAIDs after 20 weeks gestation — premature ductal closure

Activity restriction in myopericarditis: 3–6 months

Idiopathic recurrent pericarditis mortality: ~0% — reassure patients

Board Question Stem Patterns

"32-year-old man treated 4 months ago for acute pericarditis with ibuprofen for 2 weeks. Returns with recurrent sharp pleuritic chest pain relieved by leaning forward. ECG shows diffuse ST elevation. CRP 65."

→ Answer: Restart NSAID + add colchicine for ≥6 months, slow taper based on CRP normalization. Counsel that first episode was undertreated (no colchicine).

"Patient was on colchicine 0.6 mg BID + ibuprofen, doing well, stopped both 2 weeks ago. Now with recurrent symptoms."

→ Answer: Resume same regimen, continue for ≥6 months with gradual taper.

"Patient on prednisone 15 mg/day for third recurrence flares each time prednisone is tapered below 10 mg."

→ Answer: Initiate rilonacept (or anakinra) and begin steroid taper; ensure colchicine continued.

"30-year-old at 26 weeks gestation with recurrence; currently on ibuprofen + colchicine."

→ Answer: Stop ibuprofen (ductal closure risk), continue colchicine, add low-dose prednisone.

"Patient on chronic colchicine prescribed clarithromycin, presents with diarrhea, pancytopenia, myalgia."

→ Answer: Colchicine toxicity from CYP3A4/P-gp interaction; stop colchicine, supportive care, prevent recurrence with medication reconciliation.

"Patient 3 weeks post-CABG with pleuritic chest pain, low-grade fever, friction rub, small effusion."

→ Post-pericardiotomy syndrome → NSAID (aspirin preferred post-CABG) + colchicine.

"Chronic recurrent pericarditis on therapy now with new ascites, edema, elevated JVP with prominent Y descent."

→ Workup for constrictive pericarditis: CMR, right heart cath; medical therapy if active inflammation, pericardiectomy if chronic.

"Young woman with second recurrence, malar rash, joint pains, hair loss."

→ Workup SLE: ANA, dsDNA, complement, UA; treat underlying disease.

"Athlete recovered from recurrent pericarditis 4 weeks ago, asking to return to play."

→ Defer until symptom-free, normal CRP, normal ECG, normal echo ≥3 months; longer if myopericarditis.

Step 3 management: When in doubt on a stem, the default high-yield answer is "add or continue colchicine for ≥6 months and taper based on CRP." This single principle solves the majority of recurrent pericarditis questions.

Pattern 1 — The classic recurrence:

Pattern 2 — The premature taper:

Pattern 3 — Steroid-dependent:

Pattern 4 — Pregnancy:

Pattern 5 — Drug interaction patient safety:

Pattern 6 — Post-cardiac surgery:

Pattern 7 — Constriction unmasked:

Pattern 8 — Underlying autoimmune:

Pattern 9 — Activity clearance:

One-Line Recap

Recurrent pericarditis is managed by NSAID + colchicine for ≥6 months with taper guided by CRP normalization; corticosteroids are second-line at low doses with very slow taper, and IL-1 blockade (rilonacept or anakinra) is reserved for steroid-dependent or refractory cases.

High-yield recap bullets:

Board pearl: The Step 3 examiner rewards the systems-thinking clinician — written taper schedule, follow-up CRP in 1–2 weeks, medication reconciliation for colchicine interactions, vaccination updates, activity-restriction counseling, and clear return precautions are as important as the drug choice itself.

Colchicine duration in recurrence ≥6 months (vs 3 months for first episode); the most common board error is undertreatment or premature discontinuation. Reduce dose for low weight, elderly, or CrCl 30–50; avoid in dialysis; beware CYP3A4/P-gp drug interactions (clarithromycin, statins, CCBs, grapefruit).

CRP is the workhorse biomarker — continue full-dose therapy until both symptoms resolve and CRP normalizes; only then begin a slow stepwise taper (≈25% every 2 weeks), pausing or reversing at any rise. CMR with late gadolinium enhancement confirms active inflammation in ambiguous or recurrent cases and helps guide treatment duration.

Avoid first-line steroids — they paradoxically increase recurrence; if required (pregnancy >20 weeks, NSAID contraindication, autoimmune cause), use low-dose prednisone 0.2–0.5 mg/kg/day with months-long taper, always with colchicine, plus bone health protocol and stress-dose planning.

Escalate to IL-1 blockade (rilonacept FDA-approved 2021; anakinra off-label) for ≥2 recurrences or steroid dependence; screen TB and hepatitis B first, vaccinate before initiation, hold live vaccines on therapy. Always investigate underlying etiology (SLE, FMF/TRAPS, TB, malignancy, uremia, post-cardiac injury) — treating the root cause prevents endless empirical cycles.